Search results: (10000)
News Ceftarolin Fosamil in Patients with Complicated Skin and Soft Tissue Infections Admitted to ICU
In a recently published data analysis from the COVERS 3 study, the antibiotic ceftarolin fosamil was evaluated in patients with complicated skin and soft tissue infections (cSSTI) admitted to the intensive care unit (ICU), and its effectiveness was compared with patients with the same diagnosis and treatment who did not require ICU admission.
News How Common is Alpha-1 Antitrypsin Deficiency?
What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.
News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?
News How did alemtuzumab fare in real clinical practice?
A study published by authors from the University of Massachusetts in January this year in the journal Multiple Sclerosis and Related Disorders focused on the effectiveness and safety of alemtuzumab. How did it fare in real clinical practice?
News Reduction of LDL Cholesterol in the Prevention of Cardiovascular Morbidity and Mortality – Results of a Large Meta-Analysis
Elevated LDL cholesterol (LDL-c) is one of the main causes of atherosclerosis. The meta-analysis presented below examined the effect of reducing its levels on the risk of cardiovascular (CV) morbidity and mortality.
News Can antihypertensive treatment also have a beneficial effect on neurocognitive functions?
Observational studies suggest that a desirable side effect of AT1 receptor blockers for angiotensin II (sartans) could be cognitive protection of patients. A randomized study published last year evaluated the potential positive impact of candesartan and lisinopril on neurocognitive functions in older patients with mild cognitive impairment (MCI).
News Are there mutual interactions between candesartan and amlodipine in the combination therapy of hypertension?
Monotherapy is often insufficient in the treatment of hypertension; however, combining antihypertensives with different mechanisms of action can be complicated by their mutual interactions. Therefore, a study by South Korean authors examined the pharmacokinetic interactions between candesartan and amlodipine, substances that are commonly used together in combined treatment.
News Empagliflozin in the Treatment of Patients with Chronic Heart Failure
Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization due to heart failure and the risk of severe renal events in patients with type 2 diabetes mellitus. The efficacy of the SGLT2 inhibitor empagliflozin directly in the treatment of patients with chronic heart failure with reduced ejection fraction was evaluated in the EMPEROR-Reduced clinical study, the recently published results of which we summarize in the following article.
News Reducing Cardiovascular Risk in Diabetics Through Hypertension Treatment
The presence of hypertension in patients with diabetes worsens overall cardiovascular (CV) prognosis and increases the prevalence of chronic renal failure. Adequate treatment of hypertension can significantly influence the development and severity of these complications. What target blood pressure (BP) values should we aim for in diabetics, which antihypertensive therapy to choose, and why not forget about 24-hour BP monitoring?
News Administration of Low-Molecular-Weight Heparin After Hemorrhagic Stroke: What Is the Appropriate Timing?
Hemorrhagic stroke (HS) is a condition that raises doubts and concerns about anticoagulation. Is early prevention of thromboembolic complications appropriate?
News Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC
Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with significant antitumor activity against non-small cell lung cancer (NSCLC). According to the results of an international clinical study published in the Annals of Oncology, it shows very good efficacy in treating intracranial metastases in patients who experienced disease progression during therapy with second-generation ALK inhibitors.
News Thromboprophylaxis as a Common Part of Care for At-Risk Patients Requiring Hospitalization: Yes or No?
The proportion of patients requiring hospitalization who are at high risk of developing thromboembolic disease is relatively high. However, not all of these patients have this risk identified and thromboprophylaxis initiated.
News Thromboprophylaxis in Generalized Pancreatic Cancer
Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing thromboembolic disease (TED). Although anticoagulant treatment reduces the risk of TED, its positive effect on the overall survival of patients has not yet been proven.
News Position of the Aclidinium-Bromide/Formoterol-Fumarate Combination in COPD Treatment According to Current Recommendations
Dual bronchodilator therapy, which combines long-acting muscarinic antagonists (LAMA) and long-acting β-agonists (LABA), has become an integral part of the treatment for chronic obstructive pulmonary disease (COPD). Growing evidence of the efficacy and safety of the fixed combination of aclidinium-bromide/formoterol-fumarate demonstrates that this treatment meets patient needs and the current GOLD recommendations from 2019.